HypophosphatemiaPhase 2NCT06824454
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
A Phase 2 study testing Dipyridamole 75 MG in people with Hypophosphatemia and Kidney Transplantation, run by Stanford University at 1 site in United States.
Trial summary
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypophosphatemia, Kidney Transplantation
- What is being tested?
- Dipyridamole 75 MG
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteUnited States
- Study dates
- 15 May 2025to May 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult kidney transplant patients.
- No known contraindications to Dipyridamole
Who cannot join
- Contraindications to Dipyridamole.
- Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
- Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Stanford University
Stanford, California, 94304
Pari Waghela, MS, 650-724-8441, pariw@stanford.edu
Stephan Busque, MD
About this study
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
- Conditions
- Hypophosphatemia, Kidney Transplantation
- Being tested
- Dipyridamole 75 MG
- Keywords
- Post-kidney transplant care, Dipyridamole, Renal phosphate loss, Serum phosphate levels, Phosphate supplementation, Transplant graft function, Kidney transplant complications
- Medical subject headings
- Hypophosphatemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dipyridamole 75 MGDrug
Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.
| Study group | Role | What they receive |
|---|---|---|
| Treatment Group | Experimental | Participants receive Dipyridamole in addition to standard post-transplant care. Receives: Drug: Dipyridamole 75 MG |
| Control Group | No intervention | Participants in this group will receive standard post-transplant care without Dipyridamole. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Serum Phosphorus Levels After Dipyridamole Administration
This study will evaluate the effectiveness of Dipyridamole in increasing serum phosphorus levels in kidney transplant recipients with hypophosphatemia.
Measured: Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2025
- Study start15 May 2025
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypophosphatemiaStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stephan Busque, Stanford University
- Investigators
- Stephan Busque, MD, Principal investigator, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06824454
- Sponsor's protocol ID
- 76830
- Status last verified
- Jun 2026
- First submitted
- 7 Feb 2025
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
- ClinicalTrials.gov ID
- NCT06824454
- Acronym / sponsor ID
- 76830
- Conditions
- Hypophosphatemia, Kidney Transplantation
- Keywords
- Post-kidney transplant care, Dipyridamole, Renal phosphate loss, Serum phosphate levels, Phosphate supplementation, Transplant graft function, Kidney transplant complications
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Study start
- 15 May 2025 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 13 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment Group | Experimental | Drug: Dipyridamole 75 MGParticipants receive Dipyridamole in addition to standard post-transplant care. |
| Control Group | No intervention | –Participants in this group will receive standard post-transplant care without Dipyridamole. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adult kidney transplant patients.
- No known contraindications to Dipyridamole
Key exclusion criteria (3 listed)
- Contraindications to Dipyridamole.
- Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
- Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dipyridamole 75 MGDipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients. | Drug | Treatment Group |
Primary outcome
Change in Serum Phosphorus Levels After Dipyridamole Administration
Time frame: Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio
This study will evaluate the effectiveness of Dipyridamole in increasing serum phosphorus levels in kidney transplant recipients with hypophosphatemia.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Hypophosphatemia
RecruitingPhase 1/2
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
X-linked Hypophosphatemia
Not yet recruitingEarly Phase 1
Phosphate & Kidney Stones
Kidney Stones, Calcium Oxalate Kidney Stones
Recruiting
Study of the Impact of Phosphate Supplementation on FGF23 Concentrations in Patients With Hypophosphatemia
Calcium-phosphorus Metabolism
Not yet recruitingObservational study
Respiratory Quotient and Phosphate Changes During Early Critical Illness
Refeeding Syndrome, Critical Illness
Active, not recruitingObservational study
X-linked Hypophosphatemia Disease Monitoring Program
X-linked Hypophosphatemia, Hypophosphatemic Rickets
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stephan Busque, MD principal investigator
Stanford University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Dipyridamole 75 MG in people with Hypophosphatemia and Kidney Transplantation, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Serum Phosphorus Levels After Dipyridamole Administration (time frame: Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.